Tag: Advanced solid tumors

Nuvation Bio receives FDA clearance for NUV-1511 IND in advanced solid tumors

businessnewstoday- January 9, 2024

In a significant stride for cancer treatment, Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company dedicated to addressing unmet needs in oncology, announced the U.S. ... Read More

Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US

businessnewstoday- March 17, 2023

Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More

Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma

pallavi123- June 23, 2022

Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. ... Read More

BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn

pallavi123- June 14, 2022

Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More

Gan & Lee gets EMA orphan drug status for GLR2007 in glioma

pallavi123- April 6, 2021

Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type ... Read More

BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

pharmanewsdaily- October 13, 2018

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with ... Read More

Alkermes to evaluate ALKS 4230, pembrolizumab combo for solid tumors

pharmanewsdaily- September 11, 2018

Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety ... Read More

Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

pharmanewsdaily- September 8, 2018

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in ... Read More

Xencor launches phase 1 trial of XmAb20717 in advanced solid tumors

pharmanewsdaily- July 15, 2018

Xencor has launched a phase 1 clinical trial of its bispecific antibody XmAb20717, which is being developed for the treatment of multiple advanced solid tumors. ... Read More